---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-344572"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-08-11T20:04:43+00:00"
generated_at: "2026-08-11T20:06:26.994311+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kyverna Q2: net loss $38.3M ($0.63/share); RMAT for miv-cel in naSPMS; SPS BLA on track for Q4 2026

## Summary
- Cash, equivalents and marketable securities $199.4M at June 30, 2026; operating runway into 2028.
- Q2 2026 R&D expenses $24.8M; G&A expenses $14.8M; net loss $38.3M or $0.63 per share.
- FDA granted RMAT designation for miv-cel in non-active secondary progressive MS (naSPMS) based on IIT data from Stanford and UCSF.
- Rolling BLA for miv-cel in stiff person syndrome underway; CMC module submitted; completion targeted Q4 2026 with priority review and potential 2027 launch.
- KYSA-6 Phase 3 gMG enrollment expected complete mid-2027; KYSA-8 12-month and Phase 2 gMG follow-up topline data expected Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-344572
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-08-11T20:04:43+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/0001193125-26-344572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526344572/kytx-20260811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-344572
- JSON: https://secwatch.observer/filing/0001193125-26-344572.json
- Plain text: https://secwatch.observer/filing/0001193125-26-344572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.